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MinireviewReflections on a Novel
Therapeutic Candidate
gonadotropin-lutenizing hormone (LH) and follicle-stim-
ulating hormone (FSH). These, in turn, stimulate the pro-
duction of sexual hormones, a process that is linked to
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University of Texas at Austin certain diseases, including malignant breast and pros-
tate cancers. It is therefore possible that anti-GnRH ther-Austin, Texas 78712
apy may prove useful for the treatment of these cancers
and other sexual-hormone-dependent proliferative dis-
orders. Cetrorelix is a current clinical treatment that acts
Aptamers composed of L-nucleic acids, Spiegelmers,
as a GnRH receptor antagonist. It is noteworthy that
were selected to specifically bind GnRH. Spiegelmer
NOXXON chose to target the receptor ligand instead of
inhibition of GnRH activity was demonstrated in both
directly targeting the receptor; the ability to interdict
cellular and animal models. Rabbit studies showed
the function of either small hormones or their larger
minimal immunogenic response to the agents.
receptors may be a novel advantage of aptamers as
therapeutics.
Aptamers are selected nucleic acid species that typi- In order to generate anti-GnRH Spiegelmers for further
cally bind their targets with high affinities and specifici- development, Klussmann and coworkers began with
ties, rivaling those of antibodies. They are usually iso- both RNA and ssDNA libraries that contained 1015 differ-
lated from a random sequence nucleic acid library of up ent species [1]. Each library consisted of D-oligonucleo-
to 1015 species via several rounds of affinity partitioning tides with a central randomized region of 60 bases. Fig-
and in vitro amplification (see Figure 1). Unfortunately, ure 1 illustrates the selection process. Following several
aptamers composed of natural nucleotides are subject rounds of selection, the anti-GnRH aptamers were se-
to degradation by organismal or environmental nuc- quenced and assayed for their binding ability. From the
leases. RNA selection, clone A10 demonstrated the best binding
To obviate problems with stability, Fu¨rste developed with a Kd value of 92  12 nM; DNA aptamer clone S42a variation on the “reflection selection” pioneered by demonstrated the best binding with a Kd value of 55 Peter Kim and coworkers [3, 4, 6]. These researchers 7 nM. The Spiegelmers have binding affinities that are
selected natural L-amino acid peptides that bound to similar to those of other aptamers [9] and that approach
D-peptide targets; synthesis of the selected sequences those of antibodies, which typically have a Kd value lessas D-peptides resulted in compounds that bound to than 10 nM.
the natural L-peptide targets. Similarly, D-deoxyribose The specificities of the Spiegelmers also proved to be
aptamers selected against synthetic D-peptide targets suitable for further development. Chicken LHRH, which
can be resynthesized using L-nucleotides. The resultant differs from GnRH by only one amino acid, bound 50-fold
L-oligonucleotide “Spiegelmers” (from the German worse to the RNA Spiegelmer [1]. The DNA Spiegelmer
“spiegel,” for mirror) will again bind the naturally oc- bound the chicken protein over 400-fold more poorly
curring L-peptide targets with similar specificity and af- than the human protein. Similarly, buserelin, a GnRH
finity. This was demonstrated by Fu¨rste in his selections analog, showed an affinity difference of 1000-fold for the
against mirror-image adenosine and arginine molecules DNA Spiegelmer. No binding to the unrelated proteins
[3, 4] and later by Bartel in a selection against D-vaso- vasopressin or oxytocin could be detected.
pressin, a nine-residue cyclic peptide [5]. Spiegelmers While aptamers are frequently overlooked as drug
are nuclease resistant because the mirror-image L-oli- candidates, the process by which they can be optimized
gonucleotides are not found in nature and most for pharmaceutical applications is in fact very flexible
nucleases have instead evolved to recognize at least when compared with the laborious medicinal chemistry
some portion of the natural D-sugars. The combination procedures common to small-molecule drug design. For
of low Kd values, high specificity, and nuclease resis- example, to minimize the amount of material that would
tance is potentially attractive for therapeutic develop- have to be synthesized for further studies (and eventu-
ment, yet the path from academic discovery to clinical ally for applications), the deletion constructs of the ap-
application is fraught with difficulties, as most biotech- tamers were generated, and the RNA aptamer was
nology companies eventually realize. readily truncated to 50 nucleotides and the DNA aptamer
Thus, it is all the more remarkable that Klussmann to 60 nucleotides [1]. The aptamers were then directly
and his coworkers at NOXXON have managed to shep- synthesized using L-nucleotide phosphoramidites. The
herd the scientific invention to the point of being a poten- binding affinities of the truncated species rose slightly:
tial pharmaceutical candidate [1, 2]. As with other bio- the DNA Spiegelmer had a Kd value of 263 nM, while
technology companies, one of the first problems the RNA Spiegelmer had a Kd value of 190 nM. Even
NOXXON faced was choosing an interesting target for after inversion, the Spiegelmers maintained their binding
pharmaceutical development. In this respect, GnRH is specificities.
a decapeptide that binds gonadotrophic cell receptors These proof-of-principle demonstrations of the Spie-
on the pituitary gland. Binding results in secretion of gelmer technology were quickly followed by attempts
to move the molecules from mere characterizations to
efficacy studies. The ability of the Spiegelmers to inhibit1Correspondence: andy.ellington@mail.utexas.edu
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tamer to VEGF165. Wiles assayed for activity in tissue
culture [7], and Floege conducted studies in rats [8].
The NOXXON team bridged this gap using a well-studied
animal model of GnRH regulation, castrated male Wistar
Shoe rats [2]. In these animals, LH levels are high as a
result of low testosterone levels. However, the LH level
in plasma can be returned to normal by inhibiting GnRH
activity (for example, by the peptide drug mentioned
earlier, Cetrorelix, a GnRH receptor antagonist). Just as
the lengths of the Spiegelmers were handily manipu-
lated, their pharmacokinetics could be rationally engi-
neered by the addition of a 40 kDa polyethylene glycol
(PEG) moiety to the 5 end of NOX 1255, creating NOX
1257. The drug candidate NOX 1255 was administered
subcutaneously, while the modified NOX 1257 was ad-
ministered intravenously. The unmodified Spiegelmer
maximally suppressed serum LH levels 1.5 hr after ad-
ministration and maintained suppression for 4.5 hr. The
modified Spiegelmer reduced LH levels to that of intact
rats for 48 hr. These effects were similar to those ob-
served with Cetrorelix. While this was an amazing dem-
onstration of the viability of Spiegelmers as therapeutic
agents, the fact remains that the affinities and/or sys-
temic availabilities of the Spiegelmers may yet limit their
applicability. The nucleic acid drugs had to be adminis-
tered at molar amounts 30-fold higher than the peptide
Figure 1. In Vitro Selection Process for DNA Aptamers and Spie- Cetrorelix to get equivalent effects, yet were on the order
gelmers of 20 times larger. Given the likely difficulties and costs
(1), Single-stranded, randomized D-DNA pool containing approxi- of synthesizing Spiegelmers relative to small organics,
mately 1015 different species; (2), DNA pool is incubated with target
this might ultimately limit their viability as drug candi-molecules and allowed to bind; (3), nonbinding species are parti-
dates.tioned away from binding species; (4), binding species are PCR
amplified; (5), PCR product is single-strand separated, and the lead-
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